BioSpace News Archive

The primary cause of malignant mesothelioma therapeutics is the prolonged exposure asbestos in the form of long thin fibers and hydrated silicates.

RB announces the launch of a global initiative to generate high-quality scientific research-based evidence to inform public health recommendations and promote behaviors that improve global hygiene.

New Telemedicine Solution allows the MolecuLight i:X Device to be used at the Bedside for Synchronous Interpretation of the Images by Remote Wound Care Clinicians

National Recognition Spotlights Walgreens Training and Job Readiness Programs for People with Disabilities

Alexion Pharmaceuticals, Inc. announced that the Company will report its financial results for the second quarter ended June 30, 2020 before the US financial markets open on July 30, 2020.

Sales of $18.3 billion reflecting a decline of 10.8%, operational decline of 9.0%* and adjusted operational decline of 8.8%*, primarily driven by the negative impact of the COVID-19 pandemic

Compugen Ltd., a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced that the Company will release its second quarter 2020 financial results on Thursday, July 30, 2020 before the U.S. financial markets open.

Humanigen’s investigational monoclonal antibody, lenzilumab, was developed using Catalent’s proprietary GPEx® cell line development technology

Kintai Therapeutics, a pioneer in unlocking the power of the human enteric signaling network and its signals throughout the body to combat disease and promote health, announced today that it is in the initial stages of combining its operations and talent with fellow Flagship Labs-founded company Senda Biosciences.

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has completed its clinical trial agreement with Westchester Research Center at Westchester General Hospital in Miami, Florida, for its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for COVID-19.